Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

“The number one reason patients stop taking Wegovy or Mounjaro is gastrointestinal distress,” says Curran. “The nausea, vomiting, diarrhea, and constipation can be really intense, especially if a dose ...

Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...